Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Navtemadlin by Kartos Therapeutics for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis): Likelihood of Approval
Navtemadlin is under clinical development by Kartos Therapeutics and currently in Phase III for Chronic Idiopathic Myelofibrosis (Primary Myelofibrosis). According...
Navtemadlin by Kartos Therapeutics for Endometrial Cancer: Likelihood of Approval
Navtemadlin is under clinical development by Kartos Therapeutics and currently in Phase III for Endometrial Cancer. According to GlobalData, Phase...
Navtemadlin by Kartos Therapeutics for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Navtemadlin is under clinical development by Kartos Therapeutics and currently in Phase I for Refractory Acute Myeloid Leukemia. According to...
Navtemadlin by Kartos Therapeutics for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Navtemadlin is under clinical development by Kartos Therapeutics and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to...
Navtemadlin by Kartos Therapeutics for Merkel Cell Carcinoma: Likelihood of Approval
Navtemadlin is under clinical development by Kartos Therapeutics and currently in Phase II for Merkel Cell Carcinoma. According to GlobalData,...